Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free VCYT Stock Alerts

Veracyte (VCYT) Competitors

Veracyte logo
$46.32 0.00 (0.00%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$46.26 -0.05 (-0.12%)
As of 07/31/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

VCYT vs. TWST, BTSG, FMS, HIMS, and PACS

Should you buy Veracyte stock or one of its competitors? MarketBeat compares Veracyte with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Veracyte include Twist Bioscience (TWST), BrightSpring Health Services (BTSG), Fresenius Medical Care AG & Co. KGaA (FMS), Hims & Hers Health (HIMS), and PACS Group (PACS).

How does Veracyte compare to Twist Bioscience?

Veracyte (NASDAQ:VCYT) and Twist Bioscience (NASDAQ:TWST) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

In the previous week, Veracyte had 11 more articles in the media than Twist Bioscience. MarketBeat recorded 19 mentions for Veracyte and 8 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 1.24 beat Veracyte's score of 0.63 indicating that Twist Bioscience is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veracyte
7 Very Positive mention(s)
0 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Twist Bioscience
4 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Veracyte has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.11, indicating that its stock price is 111% more volatile than the broader market.

Veracyte has a net margin of 20.37% compared to Twist Bioscience's net margin of -19.85%. Veracyte's return on equity of 9.26% beat Twist Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Veracyte20.37% 9.26% 8.61%
Twist Bioscience -19.85%-26.73%-19.15%

Veracyte currently has a consensus target price of $57.38, indicating a potential upside of 23.87%. Twist Bioscience has a consensus target price of $90.30, indicating a potential downside of 1.37%. Given Veracyte's higher possible upside, equities analysts clearly believe Veracyte is more favorable than Twist Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veracyte
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.60
Twist Bioscience
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.70

Veracyte has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veracyte$561.90M6.58$66.35M$1.4132.85
Twist Bioscience$409.48M13.92-$77.67M-$1.33N/A

Summary

Veracyte beats Twist Bioscience on 10 of the 15 factors compared between the two stocks.

How does Veracyte compare to BrightSpring Health Services?

Veracyte (NASDAQ:VCYT) and BrightSpring Health Services (NASDAQ:BTSG) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

Veracyte has a net margin of 20.37% compared to BrightSpring Health Services' net margin of 2.55%. BrightSpring Health Services' return on equity of 16.73% beat Veracyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Veracyte20.37% 9.26% 8.61%
BrightSpring Health Services 2.55%16.73%5.24%

BrightSpring Health Services has higher revenue and earnings than Veracyte. Veracyte is trading at a lower price-to-earnings ratio than BrightSpring Health Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veracyte$561.90M6.58$66.35M$1.4132.85
BrightSpring Health Services$12.91B0.91$190.67M$1.4142.35

Veracyte has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market. Comparatively, BrightSpring Health Services has a beta of 1.88, meaning that its stock price is 88% more volatile than the broader market.

Veracyte presently has a consensus price target of $57.38, suggesting a potential upside of 23.87%. BrightSpring Health Services has a consensus price target of $70.12, suggesting a potential upside of 17.43%. Given Veracyte's higher probable upside, equities analysts plainly believe Veracyte is more favorable than BrightSpring Health Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veracyte
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.60
BrightSpring Health Services
0 Sell rating(s)
1 Hold rating(s)
18 Buy rating(s)
1 Strong Buy rating(s)
3.00

In the previous week, BrightSpring Health Services had 2 more articles in the media than Veracyte. MarketBeat recorded 21 mentions for BrightSpring Health Services and 19 mentions for Veracyte. BrightSpring Health Services' average media sentiment score of 0.91 beat Veracyte's score of 0.63 indicating that BrightSpring Health Services is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veracyte
7 Very Positive mention(s)
0 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
BrightSpring Health Services
8 Very Positive mention(s)
1 Positive mention(s)
10 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

BrightSpring Health Services beats Veracyte on 8 of the 13 factors compared between the two stocks.

How does Veracyte compare to Fresenius Medical Care AG & Co. KGaA?

Veracyte (NASDAQ:VCYT) and Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Veracyte. Fresenius Medical Care AG & Co. KGaA is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veracyte$561.90M6.58$66.35M$1.4132.85
Fresenius Medical Care AG & Co. KGaA$22.20B0.62$1.11B$1.9013.51

8.4% of Fresenius Medical Care AG & Co. KGaA shares are owned by institutional investors. 1.6% of Veracyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Veracyte had 15 more articles in the media than Fresenius Medical Care AG & Co. KGaA. MarketBeat recorded 19 mentions for Veracyte and 4 mentions for Fresenius Medical Care AG & Co. KGaA. Fresenius Medical Care AG & Co. KGaA's average media sentiment score of 1.78 beat Veracyte's score of 0.63 indicating that Fresenius Medical Care AG & Co. KGaA is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veracyte
7 Very Positive mention(s)
0 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Fresenius Medical Care AG & Co. KGaA
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Veracyte has a beta of 1.93, suggesting that its share price is 93% more volatile than the broader market. Comparatively, Fresenius Medical Care AG & Co. KGaA has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

Veracyte has a net margin of 20.37% compared to Fresenius Medical Care AG & Co. KGaA's net margin of 4.88%. Veracyte's return on equity of 9.26% beat Fresenius Medical Care AG & Co. KGaA's return on equity.

Company Net Margins Return on Equity Return on Assets
Veracyte20.37% 9.26% 8.61%
Fresenius Medical Care AG & Co. KGaA 4.88%8.90%4.05%

Veracyte presently has a consensus target price of $57.38, suggesting a potential upside of 23.87%. Fresenius Medical Care AG & Co. KGaA has a consensus target price of $23.95, suggesting a potential downside of 6.68%. Given Veracyte's stronger consensus rating and higher probable upside, equities analysts plainly believe Veracyte is more favorable than Fresenius Medical Care AG & Co. KGaA.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veracyte
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.60
Fresenius Medical Care AG & Co. KGaA
5 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.55

Summary

Veracyte beats Fresenius Medical Care AG & Co. KGaA on 12 of the 17 factors compared between the two stocks.

How does Veracyte compare to Hims & Hers Health?

Hims & Hers Health (NYSE:HIMS) and Veracyte (NASDAQ:VCYT) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

In the previous week, Hims & Hers Health had 5 more articles in the media than Veracyte. MarketBeat recorded 24 mentions for Hims & Hers Health and 19 mentions for Veracyte. Veracyte's average media sentiment score of 0.63 beat Hims & Hers Health's score of 0.22 indicating that Veracyte is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hims & Hers Health
5 Very Positive mention(s)
3 Positive mention(s)
9 Neutral mention(s)
5 Negative mention(s)
2 Very Negative mention(s)
Neutral
Veracyte
7 Very Positive mention(s)
0 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Hims & Hers Health currently has a consensus price target of $31.43, suggesting a potential upside of 13.12%. Veracyte has a consensus price target of $57.38, suggesting a potential upside of 23.87%. Given Veracyte's stronger consensus rating and higher probable upside, analysts clearly believe Veracyte is more favorable than Hims & Hers Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hims & Hers Health
1 Sell rating(s)
11 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.19
Veracyte
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.60

Veracyte has a net margin of 20.37% compared to Hims & Hers Health's net margin of -0.56%. Veracyte's return on equity of 9.26% beat Hims & Hers Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Hims & Hers Health-0.56% 6.10% 1.52%
Veracyte 20.37%9.26%8.61%

Hims & Hers Health has a beta of 2.35, suggesting that its stock price is 135% more volatile than the broader market. Comparatively, Veracyte has a beta of 1.93, suggesting that its stock price is 93% more volatile than the broader market.

Hims & Hers Health has higher revenue and earnings than Veracyte. Hims & Hers Health is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hims & Hers Health$2.37B2.71$128.37M-$0.09N/A
Veracyte$561.90M6.58$66.35M$1.4132.85

63.5% of Hims & Hers Health shares are owned by institutional investors. 11.8% of Hims & Hers Health shares are owned by company insiders. Comparatively, 1.6% of Veracyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Veracyte beats Hims & Hers Health on 11 of the 17 factors compared between the two stocks.

How does Veracyte compare to PACS Group?

PACS Group (NYSE:PACS) and Veracyte (NASDAQ:VCYT) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

In the previous week, Veracyte had 11 more articles in the media than PACS Group. MarketBeat recorded 19 mentions for Veracyte and 8 mentions for PACS Group. PACS Group's average media sentiment score of 1.16 beat Veracyte's score of 0.63 indicating that PACS Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PACS Group
6 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Veracyte
7 Very Positive mention(s)
0 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Veracyte has a net margin of 20.37% compared to PACS Group's net margin of 4.49%. PACS Group's return on equity of 26.47% beat Veracyte's return on equity.

Company Net Margins Return on Equity Return on Assets
PACS Group4.49% 26.47% 4.36%
Veracyte 20.37%9.26%8.61%

PACS Group has higher revenue and earnings than Veracyte. PACS Group is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PACS Group$5.43B1.34$191.54M$1.5629.56
Veracyte$561.90M6.58$66.35M$1.4132.85

PACS Group has a beta of -0.08, meaning that its share price is 108% less volatile than the broader market. Comparatively, Veracyte has a beta of 1.93, meaning that its share price is 93% more volatile than the broader market.

PACS Group presently has a consensus target price of $50.60, suggesting a potential upside of 9.72%. Veracyte has a consensus target price of $57.38, suggesting a potential upside of 23.87%. Given Veracyte's higher possible upside, analysts plainly believe Veracyte is more favorable than PACS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PACS Group
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71
Veracyte
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.60

Summary

Veracyte beats PACS Group on 8 of the 14 factors compared between the two stocks.

Get Veracyte News Delivered to You Automatically

Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VCYT vs. The Competition

Export
MetricVeracyteBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.70B$3.54B$6.85B$12.42B
Dividend YieldN/A3.78%2.59%10.03%
P/E Ratio32.857.38282.3024.66
Price / Sales6.581,200.34563.1275.93
Price / Cash31.1044.8028.6046.71
Price / Book2.8016.9610.966.07
Net Income$66.35M-$12.56M$3.49B$347.99M
7 Day Performance-16.71%-1.77%-0.64%-0.44%
1 Month Performance-18.85%-8.39%-5.23%-4.81%
1 Year Performance95.94%48.40%61.97%18.61%

Veracyte Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VCYT
Veracyte
4.1872 of 5 stars		$46.32
flat		$57.38
+23.9%		+95.9%$3.70B$561.90M32.85790
TWST
Twist Bioscience
1.427 of 5 stars		$87.45
-6.8%		$90.30
+3.3%		+171.8%$5.84B$376.57MN/A990
BTSG
BrightSpring Health Services
4.9067 of 5 stars		$70.50
-0.3%		$70.12
-0.5%		+204.0%$13.95B$12.91B50.0023,500
FMS
Fresenius Medical Care AG & Co. KGaA
3.8327 of 5 stars		$24.08
-0.1%		$28.00
+16.3%		+2.2%$12.95B$19.36B12.671,488
HIMS
Hims & Hers Health
3.151 of 5 stars		$32.69
-0.5%		$30.70
-6.1%		-55.6%$7.60B$2.35BN/A2,442

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:VCYT) was last updated on 8/3/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
“The unseen winner of the AI race” is not SpaceX
Marc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...
Chaikin Analytics | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel
What's the Best Way to Lower RMD Taxes?
Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...
SmartAsset | Sponsoredtc pixel